Heron Therapeutics (HRTX) Operating Leases: 2019-2025
Historic Operating Leases for Heron Therapeutics (HRTX) over the last 6 years, with Sep 2025 value amounting to $780,000.
- Heron Therapeutics' Operating Leases rose 49.43% to $780,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $780,000, marking a year-over-year increase of 49.43%. This contributed to the annual value of $2.8 million for FY2023, which is 49.08% down from last year.
- Heron Therapeutics' Operating Leases amounted to $780,000 in Q3 2025, which was down 49.32% from $1.5 million recorded in Q2 2025.
- Heron Therapeutics' 5-year Operating Leases high stood at $13.8 million for Q1 2021, and its period low was $522,000 during Q3 2024.
- For the 3-year period, Heron Therapeutics' Operating Leases averaged around $2.4 million, with its median value being $2.0 million (2024).
- In the last 5 years, Heron Therapeutics' Operating Leases tumbled by 85.24% in 2024 and then skyrocketed by 49.43% in 2025.
- Quarterly analysis of 5 years shows Heron Therapeutics' Operating Leases stood at $8.0 million in 2021, then tumbled by 31.23% to $5.5 million in 2022, then crashed by 49.08% to $2.8 million in 2023, then crashed by 85.24% to $522,000 in 2024, then skyrocketed by 49.43% to $780,000 in 2025.
- Its Operating Leases stands at $780,000 for Q3 2025, versus $1.5 million for Q2 2025 and $522,000 for Q3 2024.